

Cloning and Mutagenesis Market

<https://marketpublishers.com/r/C9CC12BB30B2EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,950.00 (Single User License)

ID: C9CC12BB30B2EN

Abstracts

Upcoming research reports. Delivery timeline: 4 weeks

Cloning and mutagenesis are molecular biology techniques used to manipulate DNA for research, therapeutic, or industrial applications. The cloning and mutagenesis market is mainly driven by factors such as growing advancements in genomic technologies, increasing focus on personalized approach to therapeutics and increasing prevalence of genetic diseases. However, complexity of the techniques employed for cloning and mutagenesis along with few ethical concerns are expected to pose challenges to the market growth.

Cloning and mutagenesis market- global forecast to 2030

Global Cloning and Mutagenesis Market Dynamics

DRIVER: Growing advancements in genomic technologies

Advancements in genomic technologies have transformed the field of cloning and mutagenesis, making it a powerful driver for the market. Modern genomic tools have significantly improved the precision and efficiency of cloning and mutagenesis processes. Technologies like DNA printing enable the creation of synthetic genes without requiring a template. This reduces the dependency on natural DNA samples and accelerates cloning workflows. Moreover, Genomic advancements have brought automation and scalability to cloning and mutagenesis. NGS allows rapid verification of cloning and mutagenesis results, ensuring higher accuracy in applications like gene therapy and diagnostics.

RESTRAINT: Complexity of techniques

The complexity of techniques in cloning and mutagenesis acts as a significant restraint to market growth, particularly for smaller organizations or less-experienced users. Many cloning and mutagenesis techniques are intricate and require advanced skills and training. Processes like PCR, restriction digestion, ligation, and transformation demand a deep understanding of molecular biology and biochemistry in case of cloning. Even small errors, such as incorrect primer design or poor reaction conditions, can lead to failed experiments. Mutagenesis requires precision in designing primers and understanding the gene of interest. Achieving site-specific changes without introducing off-target effects can be technically challenging.

Recent Developments:

In May 2022, Qiagen acquired BLIRT, QIAGEN N.V. announced the acquisition of a 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry. This strategic move aims to enhance QIAGEN's capabilities in enzyme development and production, thereby strengthening its sample technologies and expanding its global presence. The integration of BLIRT's specialized enzyme portfolio is expected to create additional growth opportunities for QIAGEN's existing offerings.

In February 2022, Tamara Bio, Inc., a central hub for cell and general processing in Japan, announced the expansion of its production facilities. The newly established laboratory will focus on manufacturing products such as cancer immunotherapy drugs, gene therapies, DNA and RNA vaccines, and leveraging cloning and mutagenesis techniques for regenerative medicine applications.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 REGIONS COVERED
- 1.4 YEARS CONSIDERED
- 1.5 CURRENCY CONSIDERED
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 GLOBAL MARKET ESTIMATION
 - 2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS
 - 2.2.2 SEGMENT ASSESSMENT METHODOLOGY (TOP DOWN APPROACH)
- 2.3 MARKET GROWTH FORECAST
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS

- 5.2.2 RESTRAINTS
- 5.2.3 OPPORTUNITIES
- 5.2.4 CHALLENGES
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 ECOSYSTEM ANALYSIS
- 5.7 TECHNOLOGY ANALYSIS
 - 5.7.1 KEY TECHNOLOGIES
 - 5.7.1.1 POLYMERASE CHAIN REACTION (PCR)
 - 5.7.1.2 NEXT-GENERATION SEQUENCING (NGS)
 - 5.7.2 COMPLIMENTARY TECHNOLOGIES
 - 5.7.2.1 CRISPR/CAS9 GENOME EDITING
- 5.8 PORTER'S FIVE FORCES ANALYSIS
 - 5.8.1 THREAT OF NEW ENTRANTS
 - 5.8.2 THREAT OF SUBSTITUTES
 - 5.8.3 BARGAINING POWER OF SUPPLIERS
 - 5.8.4 BARGAINING POWER OF BUYERS
 - 5.8.5 INTENSITY OF COMPETITION RIVALRY
- 5.9 REGULATORY ANALYSIS
 - 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
 - 5.9.2 REGULATORY FRAMEWORK
- 5.10 PRICING ANALYSIS
 - 5.10.1 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY KEY PLAYER, 2023
 - 5.10.2 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY REGION, 2023
- 5.11 KEY CONFERENCES AND EVENTS IN 2025-26
- 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
 - 5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
 - 5.12.2 BUYING CRITERIA FOR END USERS
- 5.13 IMPACT OF AI/GENERATIVE AI ON CLONING & MUTAGENESIS MARKET
- 5.14 INVESTMENT AND FUNDING ACTIVITIES

6 CLONING & MUTAGENESIS MARKET, BY OFFERINGS

- 6.1 INTRODUCTION
- 6.2 PRODUCT

- 6.2.1 CLONING KITS
- 6.2.2 MUTAGENESIS KITS
- 6.2.3 OTHER PRODUCTS
- 6.3 SERVICE

7 CLONING & MUTAGENESIS MARKET, BY TECHNIQUE

- 7.1 INTRODUCTION
- 7.2 TOPO PCR CLONING
- 7.3 BLUNT END CLONING
- 7.4 SEAMLESS CLONING
- 7.5 SITE-DIRECTED MUTAGENESIS
- 7.6 OTHER TECHNIQUES

8 CLONING & MUTAGENESIS MARKET, BY APPLICATION

- 8.1 INTRODUCTION
- 8.2 RESEARCH
- 8.3 THERAPEUTIC
- 8.4 OTHER APPLICATIONS

9 CLONING & MUTAGENESIS MARKET, BY END USER

- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 9.3 CROs & CMOs
- 9.4 ACADEMIC & RESEARCH INSTITUTES
- 9.5 DIAGNOSTIC LABORATORIES

10 CLONING & MUTAGENESIS MARKET, BY REGION

- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
 - 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 - 10.2.2 US
 - 10.2.3 CANADA
- 10.3 EUROPE
 - 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
 - 10.3.2 GERMANY

- 10.3.3 UK
- 10.3.4 FRANCE
- 10.3.5 ITALY
- 10.3.6 SPAIN
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
 - 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 - 10.4.2 CHINA
 - 10.4.3 JAPAN
 - 10.4.4 INDIA
 - 10.4.5 AUSTRALIA
 - 10.4.5 SOUTH KOREA
 - 10.4.6 REST OF APAC
- 10.5 LATIN AMERICA
 - 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 - 10.5.1 BRAZIL
 - 10.5.2 MEXICO
 - 10.5.3 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST
 - 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
 - 10.6.1 GCC COUNTRIES
 - 10.6.2 REST OF MIDDLE EAST
- 10.7 AFRICA
 - 10.6.1 MACROECONOMIC OUTLOOK FOR AFRICA

Note: This section will provide market sizes & forecast by phase, service type, therapy area, modality, delivery model, study design, and end user for each region and country.

11 COMPETITIVE LANDSCAPE

- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
- 11.3 REVENUE SHARE ANALYSIS, 2021-2023
- 11.4 MARKET SHARE ANALYSIS, 2023
- 11.5 CLONING & MUTAGENESIS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2023
 - 11.5.1 STARS
 - 11.5.2 EMERGING LEADERS
 - 11.5.3 PERVASIVE PLAYERS
 - 11.5.4 PARTICIPANTS

11.6 COMPANY FOOTPRINT, KEY PLAYERS, 2023

11.6.1 COMPANY FOOTPRINT

11.6.2 REGIONAL FOOTPRINT

11.6.3 PRODUCTS FOOTPRINT

11.6.4 TECHNIQUE FOOTPRINT

11.6.5 APPLICATION FOOTPRINT

11.7 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023

11.7.1 PROGRESSIVE COMPANIES

11.7.2 RESPONSIVE COMPANIES

11.7.3 DYNAMIC COMPANIES

11.7.4 STARTING BLOCKS

11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

11.7.5.1 DETAILED LIST OF KEY STARTUPS/ SMES

11.7.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING

PLAYERS/STARTUPS

11.8 BRAND/ SERVICE COMPARATIVE ANALYSIS

11.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE CLONING & MUTAGENESIS MARKET

11.10 COMPETITIVE SCENARIO AND TRENDS

11.9.1 PRODUCT/SERVICE LAUNCHES

11.9.2 DEALS

11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

12.1 KEY PLAYERS

12.1.1 THERMO FISHER SCIENTIFIC INC. (PPD, INC.)

12.1.2 AGILENT TECHNOLOGIES, INC.

12.1.3 CHARLES RIVER LABORATORIES

12.1.4 GENSCRIPT

12.1.5 NEW ENGLAND BIOLABS

12.1.6 MERCK KGAA

12.1.7 BIO-RAD LABORATORIES

12.1.8 DANAHER CORPORATION

12.1.9 TAKARA BIO

12.1.10 PROMEGA

12.1.11 TRANSGEN BIOTECH CO., LTD.

12.1.12 JENA BIOSCIENCE GMBH

12.1.13 ASSAY GENIE

Note: Above list is an indicative list of companies. Details on business overview, financial information, service portfolio, recent developments, and MarketsandMarkets view will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.

13 APPENDIX

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

13.3 AVAILABLE CUSTOMIZATIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS

Note: The given segmentation is tentative and subject to change during the course of research.

I would like to order

Product name: Cloning and Mutagenesis Market

Product link: <https://marketpublishers.com/r/C9CC12BB30B2EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9CC12BB30B2EN.html>